Armata Pharmaceuticals (ARMP) AI Stock Analysis

• Market Cap: $68.41M
• Dividend Yield: N/A
• Average Volume (3M): 498.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: N/A
• EPS Growth: 99.47%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 36,193,478
• 10 Day Avg. Volume: 22,011
• 30 Day Avg. Volume: 498,152
• PEG Ratio: 0.02
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 2.31
• Enterprise Value/Gross Profit: 41.24
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: $9.00
• Price Target Upside: 376.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: $2.00 ▲(5.82%Upside)

Armata Pharmaceuticals faces significant financial challenges, heavily impacting its overall score. The strong technical analysis and positive corporate event regarding the trial results provide some optimism, but poor financials and valuation metrics weigh heavily on the stock's outlook.

Positive Factors

Clinical Success

Armata announced a very big clinical win as well as a defining moment for bacteriophage therapy.

Funding and Support

Armata Pharmaceuticals has secured an additional $4.65 million award from the U.S. Department of Defense, increasing total non-dilutive funding for AP-SA02 to $26.2 million.

Negative Factors

Clinical Trial Risks

There are risks to achieving the price target, including potential failed or inconclusive clinical trials and inability to secure adequate funding for drug development.

Financial Risks

The company ended the year with $14.8 million in cash, and has a loan with an annual interest rate of 14% maturing in 2026.

Armata Pharmaceuticals Business Overview & Revenue Model

Company Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

How the Company Makes Money

Armata Pharmaceuticals makes money primarily through the development and potential commercialization of its bacteriophage-based therapies. The company's revenue model includes collaborations and partnerships with other pharmaceutical companies and research organizations to advance its research and development efforts. These partnerships may involve licensing agreements, milestone payments, and potential royalties from successfully developed and marketed therapies. Additionally, Armata may receive funding through government grants and contracts aimed at supporting innovative treatments for antibiotic-resistant infections. As the company progresses in clinical trials and moves closer to regulatory approval, it positions itself to earn revenue from the eventual sale and distribution of its therapeutic products.

Armata Pharmaceuticals Financial Statement Overview

Summary

Armata Pharmaceuticals is experiencing significant financial distress with declining revenue and persistent losses. The balance sheet shows negative equity, indicating insolvency risks, and cash flow relies heavily on financing activities.

Income Statement

Armata Pharmaceuticals shows a significant decline in revenue with no revenue reported in the most recent year from $4.5 million the previous year. The company has been consistently operating at a loss, with increasing negative EBIT and EBITDA margins. The net profit margin is also negative due to substantial net losses over the years, indicating financial distress.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning as liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, but high total liabilities relative to assets suggest a heavily leveraged position. The equity ratio is negative, indicating insolvency risks.

Cash Flow

Free cash flow remains negative, but there is a minor improvement in free cash flow growth due to reduced negative cash flow. The operating cash flow is significantly negative and larger than net income, suggesting inefficient cash management. The company relies on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.24M	5.17M	4.53M	5.51M	4.47M	823.00K
Gross Profit	540.00K	3.85M	-29.24M	4.62M	-15.54M	-13.62M
EBITDA	13.48M	-6.85M	-39.92M	-36.05M	-22.65M	-20.44M
Net Income	-426.00K	-18.92M	-69.05M	-36.92M	-23.16M	-22.18M
Balance Sheet
Total Assets	87.25M	86.44M	98.36M	95.83M	69.77M	39.52M
Cash, Cash Equivalents and Short-Term Investments	11.69M	9.29M	13.52M	14.85M	10.29M	9.65M
Total Debt	106.96M	126.52M	120.37M	48.81M	37.99M	13.15M
Total Liabilities	141.03M	134.46M	130.43M	59.75M	44.37M	20.66M
Stockholders Equity	-53.78M	-48.02M	-32.06M	36.08M	25.40M	18.86M
Cash Flow
Free Cash Flow	-36.27M	-39.43M	-55.57M	-34.69M	-24.88M	-19.09M
Operating Cash Flow	-34.55M	-37.55M	-47.42M	-32.48M	-23.57M	-18.27M
Investing Cash Flow	-1.73M	-1.88M	-8.13M	-2.21M	-1.30M	-824.00K
Financing Cash Flow	10.01M	34.96M	53.99M	44.02M	25.52M	23.21M

Armata Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Negative. The current price of 1.89 is below the 20-day moving average (MA) of 1.94, above the 50-day MA of 1.74, and below the 200-day MA of 1.98, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 71.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARMP.

Armata Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARMP	55 Neutral	$68.41M	―	81.15%	―	―	99.47%
ALGS	53 Neutral	$45.19M	―	-60.44%	―	-76.29%	―
Sector *	51 Neutral	$7.55B	0.39	-61.90%	2.32%	17.14%	1.55%
PDSB	50 Neutral	$55.77M	―	-119.22%	―	―	25.51%
CUE	50 Neutral	$50.67M	―	-221.66%	―	13.83%	37.66%
ATNM	41 Neutral	$44.30M	―	-130.87%	―	-100.00%	30.65%
CNTX	37 Underperform	$56.29M	―	-55.59%	―	―	65.02%

Armata Pharmaceuticals Corporate Events

Armata Pharmaceuticals Elects Board Members at Annual Meeting

At the Annual Meeting of Shareholders on June 12, 2025, Armata Pharmaceuticals elected seven board members for a one-year term ending in 2026. Shareholders also approved the compensation of the company’s executive officers and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results

On May 19, 2025, Armata Pharmaceuticals announced positive topline results from its Phase 1b/2a diSArm trial, which evaluated the intravenous administration of AP-SA02 for treating complicated Staphylococcus aureus bacteremia. The study met all primary endpoints for safety, tolerability, and clinical response, showing significant improvement in clinical outcomes and prevention of relapse compared to best available antibiotic therapy. The trial’s success marks a significant advancement in phage therapy, with no serious adverse events reported, and supports further development towards a pivotal trial. Armata’s ability to produce high-purity phage therapeutics and its manufacturing capacity to produce over 10,000 full courses annually positions it strongly in the field of bacteriophage-based treatments.

The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.